Drugs / Etrolizumab
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03478956 | Mar 2018 → Dec 2019 | Crohn disease, ulcerative colitis | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT02996019 | Dec 2016 → Apr 2018 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02629744 | Dec 2015 → Jun 2016 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00694980 | Sep 2008 → Sep 2011 | ulcerative colitis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01461317 | Nov 2011 → Aug 2016 | ulcerative colitis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01336465 | Sep 2011 → Sep 2012 | ulcerative colitis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT02403323 | Jun 2015 → Oct 2023 | Crohn disease | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT02394028 | Mar 2015 → Sep 2021 | Crohn disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02136069 | Dec 2014 → Jun 2020 | ulcerative colitis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02171429 | Nov 2014 → Mar 2020 | ulcerative colitis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02163759 | Nov 2014 → Feb 2020 | ulcerative colitis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02118584 | Sep 2014 → Oct 2023 | ulcerative colitis | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT02165215 | Aug 2014 → Apr 2020 | ulcerative colitis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02100696 | May 2014 → Apr 2020 | ulcerative colitis | Hoffmann-La Roche | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-08-10 | Roche Global Development | Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis roche.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etrolizumab | “BACKGROUND: Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of the heterodimeric integrins α4β7 and αEβ7.” PMID 24814090 ↗ May 201412“Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody.” PMID 34798039 ↗ Nov 2021 |
| Known as | Anti-.beta.7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743015 ↗ |
| Known as | Anti-Beta7 Pro145223 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743015 ↗ |
| Known as | PRO-145223 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743015 ↗ |
| Known as | RG-7413 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743015 ↗ |
| Known as | rhuMAb Beta7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00694980 ↗ |
| Action | Inhibit | “anti-β7 integrin” PMID 34798039 ↗ Nov 2021 |
| Modality | Monoclonal antibody | “Etrolizumab is a humanised monoclonal antibody” PMID 24814090 ↗ May 2014 |
| Route | Intravenous | “Intravenous and subcutaneous escalating doses” NCT00694980 ↗ |
| Route | Subcutaneous | “Intravenous and subcutaneous escalating doses” NCT00694980 ↗ |
| Target | ITGB7 | “Etrolizumab is a novel, dual-action anti-β7 integrin antibody” PMID 33778929 ↗ Mar 2021 |